For over a century, it has been apparent that fresh serum contains lytic and opsonic factors that are now known as complement. Despite extensive characterization of this system, which includes more than 20 components, its function is still unfolding. The long-term goal of this proposal is to understand how the central component (C3) of this system interacts with the immune system in the acquired immune response and in clearance of encapsulated bacteria. This goal has been divided into three specific aims: (1) construction of a C3 deficient mouse; (2) determine the role of C3 in the humoral immune response; and (3) determine the role of C3 in clearance of encapsulated bacteria. As a novel approach to addressing the long-term objective, mice genetically deficient in complement C3 will be constructed using the technique of homologous recombination in embryonic stem cells. The availability of a totally C3 deficient strain of mouse (C3Def) would be highly important as the interaction between C3 and the well-characterized murine immune system could be examined in vivo for the first time. Individuals deficient in C3 are highly susceptible to repeated pyogenic infections by gram-positive organisms such as Streptococcus pneumonia and Neisseria meningococcus. This study will utilize the C3Def murine model to examine the host's defense against one of these organisms, S. pneumococcus. By clarifying the role of C3 in the humoral response to both T-dependent and T-independent antigens, these results would be important in both identifying those at risk and in designing a possible treatment for infection. For example, if the C3 ligand is found to be critical for bacterial clearance, this ligand might be used as an effective adjuvant in vaccination of immunocompromised children against encapsulated bacteria. In summary, this application proposes to develop for the first time a totally C3 deficient strain of mouse and to use this genetic model to clarify the role of C3 in both the acquired immune response and clearance of bacteria.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI036389-01A1
Application #
2072659
Study Section
Allergy and Immunology Study Section (ALY)
Project Start
1995-09-15
Project End
1998-09-14
Budget Start
1995-09-15
Budget End
1996-09-14
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Harvard University
Department
Pathology
Type
Schools of Medicine
DUNS #
082359691
City
Boston
State
MA
Country
United States
Zip Code
02115
Carroll, Michael C (2004) The complement system in B cell regulation. Mol Immunol 41:141-6
Carroll, Michael C (2004) The complement system in regulation of adaptive immunity. Nat Immunol 5:981-6
Pozdnyakova, Olga; Guttormsen, Hilde-Kari; Lalani, Farah N et al. (2003) Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3- and complement receptor 2-deficient mice. J Immunol 170:84-90
Verschoor, Admar; Brockman, Mark A; Gadjeva, Mihaela et al. (2003) Myeloid C3 determines induction of humoral responses to peripheral herpes simplex virus infection. J Immunol 171:5363-71
Buono, Chiara; Come, Carolyn E; Witztum, Joseph L et al. (2002) Influence of C3 deficiency on atherosclerosis. Circulation 105:3025-31
Shapiro, Scott; Beenhouwer, David O; Feldmesser, Marta et al. (2002) Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect Immun 70:2598-604
Han, Y; Kozel, T R; Zhang, M X et al. (2001) Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J Immunol 167:1550-7
Yan, J; Vetvicka, V; Xia, Y et al. (1999) Beta-glucan, a ""specific"" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol 163:3045-52
Boes, M; Prodeus, A P; Schmidt, T et al. (1998) A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med 188:2381-6
Boes, M; Esau, C; Fischer, M B et al. (1998) Enhanced B-1 cell development, but impaired IgG antibody responses in mice deficient in secreted IgM. J Immunol 160:4776-87

Showing the most recent 10 out of 12 publications